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Epithelial mesenchymal transition consists in the loss of apico-basal polarity and epithelial
markers as E-cadherin or integrins and acquisition of mesenchymal migratory phenotype with
markers vimentin, fibronectin and N-cadherin. During tumor progression EMT results in the
acquisition of invasive properties such as high resistance to apoptosis, properties of stem cells
and the ability to migrate allowing them to move and integrate into nearby tissue.
There is a large number of genes and signaling pathways involved including TGF-β, Wnt, Notch,
and ERK/MAPK pathways that allows the upregulation of transcriptional repressors of E-
cadherin expression like Snail or Twist. It has been seen that it is a small heterogeneous
population of cancer stem cells responsible for the initiation and metastatic growth of breast
cancer. The main objective will be to identify their markers and signaling pathways responsible
for maintenance of this BCSCs.
Changes in 
Gene regulation,
Cell adhesion,
Cytoskeletal organization
Loss of cell type specificity
Breast cancer stem cells generated through the epithelial 
mesenchymal transition
Patricia Ibars Sillés. Degree in biochemistry. 
Epithelial
Cells Mesenchymal
Cells
1. INTRODUCTION 2. TGF-β IS THE MAIN INDUCER OF EMT
The transforming growth factor beta is
overexpressed in many human cancers.
Cooperates with Wnt, Ras, Hedgehog
and Notch pathways to induce a
complete EMT.
TGF-β activates multiple signaling
pathways through TGF-βRI and TGF-βR II
that activate and phosphorylate effector
molecules as Smad2 and Smad3. These
phosphorylated form trimers with
Smad4 to enter the nucleus and bind to
transcription factors thereby promoting
the expression of target related with
proliferation, differentiation, apoptosis
and cell migration.
Figure 2: Modified from “Transcriptional crosstalk between 
TGFβ and stem cell pathways in tumor cell invasion: Role of 
EMT promoting Smad complexes” (2010).
Their most important features are the ability to self-renewal and regulating the balance
between self-renewal and differentiation. They also have a great migratory and
proliferative potential and express high levels of ABC transporters and thus, it has been
suggested to be responsible for the development of drug resistance.
3. BREAST CANCER STEM CELLS (BCSCs)
BCSCs marker
CD44+/CD24-/loLin- phenotype
HER2 overexpression
Mammosphere formation
Exclusion of fluorescent dye by a side population
Transforming growth factor-β (TGF-β)
BMP-7 expression
microRNAs
CXCR4 (Chemokine receptor)
CSCL12 expression
ESA, CK5, and α6- integrin
Aldehyde dehydrogenase-1 (ALDH1) activity
CD44
Table 1: Modified from “Breast Cancer Stem Cells, 
Pathways and Therapeutic Perspectives 2011” 
(2012).
CD44 is a target gene of β-catenin / 
TCF4. It is a membrane receptor that 
recognizes ligands of the extracellular 
matrix, whose expression has been 
linked to aggressive behavior and 
tumor metastasis.
CD24 can regulate cell adhesion by 
reducing CXCR4.
ALDH1 is responsible for the 
intracellular oxidation of aldehydes; 
thus confers resistance to alkylating
agents. It may have a role in self-
renewal of the cells oxidizing retinol 
to retinoic acid. It also increases the 
ability to form mamospheres.
CXCR4 is a receptor driving stem 
cells and tumor metastasis. 
CSCL12 is a chemokine that 
promote induction and 
migration of immune cells to the 
site of infection. CXCL12 
interacts with CXCR4 inducing 
migration and survival of 
neoplastic cells.
Figure 3: Modified from “Role of the CXCR4/CXCL12 signaling 
axis in breast cancer metastasis to the brain” (2010).
4. PATHWAYS RESPONSIBLE FOR THE MAINTENANCE OF BCSCs
One of them would be directed to resistance to chemotherapy of this stem cells: inhibitors of
these transporters ABCG2 and ABCB1, ex. Nilotinib.
Remove cancer stem cells, ex. trastuzumab led to ErbB2.
Inhibition of the pathways involved in self-renewal: cyclopamina to inhibit Smo in the Hedgehog
pathway, imatinib that negatively regulate β-catenin in the Wnt signaling and Notch-4 blocking
antibody.
Therapies targeting chemoreceptors using these breast cancer stem cells to migrate and
proteins necessary for integration with the microenvironment for example using CXCR4
antagonists.
 Inducing differentiation of breast cancer stem cells.
5. THERAPY 6. CONCLUSIONS
Epithelial mesenchymal transition generates cells with stem cell properties with
phenotype CD44+/CD24- or activity ALDH1 and these cells are enriched with tumor-initiating
cells.
These cells are responsible for the resistance to treatment of this cancer.
There is strong evidence that the crosstalk of the Hedgehog, Notch, Wnt and other keys
signaling pathways and their role in the regulation of tumor-initiating cells, can promote
tumorigenesis in breast cancer.
Regarding the treatment, the better would be the combination of different therapies
aimed at eliminating breast cancer stem cells responsible of the invasive progression tumor.
7. REFERENCES
1. A Singh and J Settleman: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741–4751
2. Mallini P, Lennard T, Kirby J, Meeson A: Epithelial to mesenchymal transition: What is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 2014, 40: 341-348.
3. Schwartz T et al.: Expression of Aldehyde Dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of ghanaian women. Cancer 2013, 119:488-494.
4. Polyak K, A. Weinberg R: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Rev. Cancer 2009, 9: 265-273.
EMT
Figure 1:  Modified from “Breast Cancer Stem Cells, Pathways and Therapeutic Perspectives 2011” (2012).
Figure 4: Wnt, Hedgehog and Notch signaling pathways regulate the maintenance of 
breast cancer stem cells controlling the transcription of various target genes associated 
with EMT and repression of E-cadherin.
